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 ARTICLE 
Management of the HIV-infected patient 
before the Development of AIDS
James A Gray, Olim Praeses
Dr. Gray was Senior President of the RMS in his day and 
during that time started the journal, 'Res Medica'. So we 
were 'well chuffed' when he offered to write an article for this 
resurrection of his creation, especially since it clarifies many 
of the incongruities presented in current literature 
concerning the clinical management of these special patients.
19th century and early 20th century 
physicians taught their students: “Know 
syphilis and you will know medicine.” In 
this last decade of the 20th century, 
physicians could justifiably substitute the 
word ‘AIDS’ for ‘syphilis’. Every aspect of 
human immunodeficiency virus (HIV) 
infection - whether the epidemiology, 
immunology, pathogenesis, diagnosis, 
management or prevention - presents an 
intellectual challenge to our profession. 
Politicians, educationalists, doctors and the 
lay public ignore this disease at their peril. 
We all have a duty to ourselves and to future 
generations to do everything possible to 
control and ultimately to eliminate HIV 
infection.
This article attempts to outline the general 
management of HIV-infected patients 
before they develop AIDS. To understand 
the philosophy behind such management, 
one must be conversant with the natural 
history of the infection. The Center of 
Communicable Disease Control (CDC),
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Atlanta, Georgia, has developed a system of 
classification which will be used throughout 
this article (see Figurel). Thus patients 
with the acute seroconversion illness which 
resembles glandular fever, if it is recognised 
for what it is - and often it is not or forgotten
New Classification S ystem
about - are classified as Group 1. There 
follows a long incubation period with a 
mean of 8-9 years (range 2-15 or longer) 
during which the patient remains largely 
well clinically (Group 2). This is the group 
upon which this article will concentrate. 
When the disease next becomes 
symptomatic the patient enters Group 3 
(formerly designated Persistent Generalised 
Lymphadenopathy or PGL) or else he or she 
develops full blown AIDS (Group 4). 
Patients with AIDS may have minimal 
symptoms - say between attacks of 
opportunistic infection - or be desperately 
ill. The subgroups within Group 4 disease 
are
Sub-group A - fever persisting for longer 
than one month, involuntary weight loss in 
excess of 10% or diarrhoea lasting for more 
than one month without an alternative 
explanation. Sub-group A corresponds with 
the previously designated AIDS related
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Group 1: Acute seroconversion 
Often mistaken for glandular fever & forgotten
Group 2: Incubation period 
Patient remains largely well for 8-9 years (±7)
E Group 3: SymptomaticFormerly Persistent Generalised Lymphadenopathy
Group 4: Full Blown AIDS
Minimal symptoms to desperately ill
Sub-group E
Those who have symptoms, tumours or 
infections which do not fit in any of the 
other CDC Group 4 sub-groups.
Sub-group A
Previously AIDS Related Complex (ARC) 
Fever > 1 month 
Involuntary weight loss >10% 
Unexplained diarrhoea > 1 month
Sub-group B
Neurological Disease 
AIDS dementia complex, Idiopathic 
myelopathy or peripheral neuropathy
Sub-group C 
Opportunistic Infections 
Often the first presentation of a patient with 
AIDS. Especially drug misusers, 
eg. Pneumocystis carinii pneumonia 
Oesophageal candidosis
Sub-group D
Tumours
eg. Kaposi's sarcoma, non-Hodgkins 
lymphoma, primary lymphoma of the brain. 
Especially male homosexuals.
F i g u r e  1: A b b r e v i a t e d  C D C  c l a ss i f i c a t i o n  o f  the n a t u r a l  h i s t or y  o f  H I V  in fe c t io n .
complex or ARC.
Sub-group B includes those patients with 
neurological disease like AIDS dementia 
complex, myelopathy or peripheral 
neuropathy without an alternative 
explanation.
Sub-group C represents those patients with 
opportunistic infections in the context of 
HIV infection or illness indicating a defect 
of cell mediated immunity. Many patients, 
especially those who have acquired their 
infection by intravenous drug misuse, first 
present with AIDS in this category by 
developing Pneumocystis carinii 
pneumonia (PCP), or other chronic or 
invasive parasitic, viral or fungal 
infections.
Sub-group D includes those patients with 
tumours such as Kaposi’s sarcoma (KS), 
non-Hodgkins lymphoma or primary 
lymphoma of the brain. Many male 
homosexuals but very few intravenous drug
misusers with HI V infection present with or 
are at some time affected by KS. The reason 
for this is not yet known.
Finally Sub-group E is a convenient 
category for patients with HIV infection 
whose symptoms, tumours or infections do 
not neatly fit into the other sub-groups of 
the CDC Group 4.
Without a clear knowledge of this 
classification, necessarily abbreviated here, 
the physician looking after HIV-infected 
patients who are asymptomatic to date 
cannot be aware of the many possible ways 
in which AIDS may present and so be able 
to investigate expeditiously and promptly 
treat serious disease when it does arise. 
Correct management of HIV infection is 
concerned with the intelligent anticipation 
of problems.
The length of any patient’s stay in Group 2 
(asymptomatic HIV infection) depends 
upon age, sex (including pregnancy), race
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fitness at the start of the illness, lifestyle eg. 
persistent drug misuse, alcoholism, 
undernutrition, and probably also the 
infecting dose or doses of HIV and whether 
such insults are continuing. Ability to avoid 
other infections eg. sexually transmitted 
disease may reduce antigen load and also 
keep the patient asymptomatic for longer. 
Education is therefore an important factor in 
patient management, not only in reducing 
the risk of infection to others, but also in the 
encouragement of a lifestyle that will delay 
the onset of AIDS in that individual. 
Another factor that may, in the future, help 
patients in Group 2 to keep well and delay 
the onset of AIDS is the judicious use of the 
anti-retroviral drug zidovudine (azido- 
thymidine, AZT or Retrovir). Antifungal, 
antiparasitic or other antiviral agents which 
are often used as secondary prophylaxis 
after AIDS has developed, may sometimes 
also be employed for primary prophylaxis. 
The decision about what drugs to use and 
when will depend on how the patient is, 
judged by regular clinical and laboratory 
screening. Whilst this monitoring and 
prophylaxis are proceeding, it is important 
to remember the psychological wellbeing of 
the HIV-infected individual who may also 
need the patient support of an experienced 
counsellor.
Expensive drugs like AZT are ill afforded 
even in the relatively affluent western 
world. In some parts of Africa where 30% 
of the population may be HIV infected, such 
therapy is simply unavailable.
A possible outline of management of the 
HIV-infected patient in CDC Group 2 
follows, but it should be remembered that 
with our rapidly increasing understanding 
of the disease and the development of new 
drugs and strategies, this may require 
radical revision within months rather than
years.
Z idovu dine
At the time of writing the results of the 
British-French collaborative study 
(Concorde) on the use of AZT versus 
placebo in asymptomatic HIV-infected 
patients are not known. An American study 
by the National Institute of Allergy and 
Infectious Diseases reported in the summer 
of 1989 that 50 of the 713 participants who 
started on the study between 3 and 30 
months before had progressed from early 
ARC (CDC Group 4 A) to more advanced 
ARC or full blown AIDS. Thirty-six of 
these 50 had been taking placebo and 14 of 
them 1,200mg AZT daily. AZT only 
seemed to benefit those with T4 lymphocyte 
counts of between 200 and 800 mm-3 
(Normal range 500-1000 mm3).
AZT is better tolerated in asymptomatic 
patients fewer of whom develop bone 
marrow toxicity than when it is given to 
patients with AIDS. The theoretical risk of 
the development of AZT resistance by HIV 
in vivo has so far not been shown although it 
has been demonstrated in vitro.
It would therefore seem likely that CDC 
Group 2 patients could benefit from early 
treatment with AZT and that, despite the 
expense, not only of the drug itself, but also 
of the mandatory monitoring for toxicity 
that should accompany its use, it may in 
future be recommended at this stage of the 
disease. The dosage will depend upon the 
the results of the Concorde study but is 
likely to be less than that presently used. 
This will probably reduce dose-related 
toxicity and of course expense.
Clinical and  laboratory  
m onitor ing
At each out-patient visit, perhaps every 3-6 
months in the apparently well patient,
Symptoms to look for:
fever dyspnoea cough 
skin rashes night sweats
weight loss oral thrush
reduced exercise tolerance
diarrhoea and vomiting
visual impairment
Less specific symptoms
headache poor memory 
undue fatigue lethargy 
malaise
Figure 2: S y m p t o m  check l is t  for  
C D C  g ro u p  2 pat ien t  consu l ta t ion .
enquiry should be made about 
symptomatology as detailed in Figure 2. 
The patient must be weighed at each 
attendance. Examination should concen­
trate on a search for lymphadenopathy, skin 
rashes and tumours, an oral inspection for 
hairy leukoplakia and candidosis and finally 
ophthalmoscopy for evidence of retinitis 
caused by HIV itself, toxoplasma and 
cytomegalovirus.
If the patient is a known intravenous drug 
misuser, he or she must be questioned about 
any continuing habit and inspected both in 
likely and unlikely sites of venous access 
for puncture marks. Consideration may be 
given to registering the patient with the 
Home Office as a drug misuser and 
supplying him or her with maintenance 
methadone as a substitute for intravenously 
administered opiates like heroin.
Basic laboratory monitoring will depend 
upon whether AZT is being used in which 
case the patient should be seen every 1-2 
months rather than less often. A full blood 
count, including platelets, should always be
done and if available, a T4 lymphocyte 
count and a check for the HIV core antigen 
P24. A fall in peripheral blood lymphocytes 
(especially the T4 cells) or platelets, the 
development of anaemia, the presence of 
antigenaemia and elevation of 6-2 
microgobulin and gamma-globulins 
generally suggest advancing disease.
It may be necessary to stop or reduce the 
dose of AZT if the erythrocytes and 
granulocytes are much depleted. 
Transfusion of blood, platelets or the 
administration of gamma-globulin may be 
indicated. A haemoglobin below 8gdL1 or 
a neutrophil count of less than 750mm 3 is 
an absolute indication for stopping AZT and 
for considering blood transfusion. AZT 
may be cautiously restarted in a reduced 
dose (i.e. less than the usual 3.5mgkg-1 
4hrly) if the haemoglobin has been well 
maintained after transfusion. AZT may be 
used occasionally as a platelet booster, but 
it is surprising how long HIV infected 
patients can tolerate very low platelet 
counts without bleeding.
The importance of monitoring T4 cells, 
other formed elements in the blood and 
antigenaemia is not simply to check for drug 
toxicity but also to anticipate if the patient is 
likely to be progressing towards CDC 
Groups 3 or 4 so that follow-up may be 
intensified and the general practitioner 
advised to refer the patient to hospital 
urgently if this seems appropriate. Early 
intervention in opportunistic infections is 
often life-saving but can only happen if 
anticipated. The earliest signs and 
symptoms must be recognised, investigated 
and appropriate treatment begun at once.
Prim ary  prophylaxis for 
opportunis t ic  infections
As about 50% of patients who progress to 
AIDS do so by developing PCP, primary
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HOW HIV HIJACKS THE BODY'S T4 CELLS
1. HIV locks onto cells that control the 
body’s natural defence system
7. the components assemble 
themselves to produce more virus 
which then buds out of the cell
2. the virus enters the cells 
and releases its genes
reverse transcriptase 
'receptor' on T4 cell
nucleus
viral RNA  cell's DNA
6. the activated cell becomes a 
factory for the virus, producing 
the necessar/components to 
make new virus particles
5. viral genes sit dormant in host cell, for months or even 
years, until the cell becomes activated, eg by an infection
3. the virus's genes are 
convened into the same 
form that is contained in the 
cell (DNA) by a molecule 
called 'reverse transcriptase'
4. the viral genes (now as DNA) become 
incorporated into the cell's DNA
prophylaxis against this disease would seem 
appropriate. Whereas cotrimoxazole 
prophylaxis against recurrence of PCP has 
been well tolerated, the administration of 
cotrimoxazole to prevent a first attack of 
PCP has been associated with a very high 
incidence of side-effects.
It is possible that inhaled pentamidine 
which again has a good record in the 
prevention of recurrences of PCP may in 
future have a place in primary prophylaxis 
but at the time of writing there is 
insufficient evidence to recommend it 
routinely. Fortnightly or 3-weekly doses of 
300mg inhaled pentamidine are generally 
safe. If bronchospasm occurs it can usually 
be controlled in the next administration by 
inhalation of 2.5mg salbutamol immedia­
tely before the pentamidine. An alternative
to inhaled pentamidine is the weekly 
administration of one tablet of 
pyrimethamine/sulfadoxine (Fansidar) 
although skin rashes and even the Stevens- 
Johnson Syndrome can result.
Other possibilities for primary prophylaxis 
which are less contentious include the 
administration of acyclovir to prevent 
Herpes simplex and Herpes zoster both of 
which can occur in milder forms without 
technically advancing the patient’s CDC 
classification to Group 4. Antifungal 
prophylaxis with ketoconazole is 
sometimes associated with hepatic toxicity 
and the newer fluconazole in a daily dose of 
50mg is more acceptable and has the 
advantage of crossing the blood-brain 
barrier and so, theoretically at least, 
lessening the risk of cryptococcal
ARTICLE
meningitis.
Primary prophylaxis against toxoplasmosis, 
cryptpsporidiosis, cytomegalovirus and 
mycobacterial infection may be goals for 
the future but often present problems of 
toxicity when tried.
C o u n s e l l i n g ,  s u p p o r t  a n d  e d u c a t i o n
In addition to the morale boosting and 
support that a trained counsellor can 
provide, opportunities frequently exist 
when risk reduction for the patient, relatives 
and consorts can be discussed and 
reinforced. The provision of condoms and 
instruction in safe sexual practices, the 
exchange of dirty for clean syringes and 
needles for the drug abuser who will not 
desist from his or her habit or the 
establishment of a maintenance methadone 
substitution programme are all areas that 
may need to be explored.
A combined team approach is essential to 
the good management of HIV infected
patients at whatever stage of their disease 
they happen to be in. Patients in the 
asymptomatic stages can enjoy a reasonably 
satisfactory lifestyle for many years if they 
are given the benefit of expert care and 
advice. New therapies may be developed. 
HIV-infected patients should therefore 
always be encouraged with a cautious but 
realistic degree of optimism.
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